电子邮件/Email
yunlongyang(at)fudan.edu.cn
教育经历及职位/Education
2019起, 复旦大学上海医学院 细胞与遗传医学系 副主任
2017起, 复旦大学上海医学院 细胞与遗传医学系，研究员
2017-2017, 瑞典卡罗林斯卡医学院，研究人员
2012-2017, 瑞典卡罗林斯卡医学院，博士后研究员
2009-2011, 瑞典卡罗林斯卡医学院，联合培养博士研究生
2006-2011, 复旦大学上海医学院，遗传学专业博士研究生
2002-2006, 同济大学生命科学与技术学院，生物技术专业本科生
主持基金/Grants
2023-2026,“万人计划”青年拔尖人才，中组部
2019-2022, 上海高校特聘教授（东方学者），上海市教委
2018-2020, 浦江人才，上海市科委
2018-2022, NSFC面上项目，中国
2017-2021, 引进人才启动基金，复旦大学
教育教学/Teaching
2023, 国家级一流本科课程 负责人，教育部
2021, 复旦大学荣誉课程 负责人，复旦大学
2021, 上海高等学校一流本科课程 负责人，上海市教委
发表论文/Publications
Google Scholar：https://scholar.google.com/citations?user=joh17pwAAAAJ&hl=en
Research Gate：https://www.researchgate.net/profile/Yunlong-Yang-13
主要研究兴趣为：1、肿瘤血管生物学及其微环境的转化医学研究；2、肿瘤、脂肪相关的代谢研究； 3、肿瘤血管、淋巴管转移不同步骤的分子机制及抗转移策略； 4、正常组织血管微环境及其病理机制的转化医学研究。
Research Interest: 1. Translational research on tumor angiogenesis and tumor microenvironment; 2. Translational research on tumor- and adipose tissue-associated metabolism; 3. Mechanistic research on tumor metastasis and anti-metastatic strategies; 4. Translational research on normal tissue vascular biology.
杨云龙，理学博士，教授，博士生导师。19篇第一/通讯作者论文发表于 Nature, Cell Metabolism, Science Translational Medicine, Gut, Advanced Functional Materials, Nature Communications, Cancer Research, PNAS等刊物(下划线标注)。代表作被选为Nature Reviews Endocrinology研究亮点、Science Translational Medicine 封面文章、Nature Communications研究亮点、被Science、Cancer Discovery等刊物报道，入选ESI高被引文章等。受邀在Seminars in Cancer Biology, Advanced Drug Delivery Reviews等刊物发表综述或社论。2011年至今发表文献53篇，影响因子总和860分，篇均=16.2。总引用近3000次。H指数为28。以第一发明人获批专利8项(ZL201711310808.X；ZL201711310791.8；ZL201810179243.4； ZL201810398743.7；ZL201810400082.7；ZL201810407248.8；ZL201910463388.1; ZL201910596001X)。
1. Sun X, Sui W, Mu Z, Xie S, Deng J, Li S, et al. Mirabegron displays anticancer effects by globally browning adipose tissues. Nature Communications. 2023 Nov 22;14(1):7610. doi: 10.1038/s41467-023-43350-8. (IF 16.6, Editors’ Highlights in Nature Communications)
2. Hui T, Fu J, Zheng B, Fu C, Zhao B, Zhang T, et al. Subtractive Nanopore Engineered MXene Photonic Nanomedicine with Enhanced Capability of Photothermia, Drug Delivery and Cellular Internalization for Synergistic Photothermal/Chemotherapy of Osteosarcoma. ACS Applied Materials & Interfaces.2023 Nov 1;15(43):50002-50014. doi: 10.1021/acsami.3c10572. (IF 9.5)
3. Yang Y, Zhong J, Cui D, Jensen LD. Up-to-date molecular medicine strategies for management of ocular surface neovascularization. Advanced Drug Delivery Reviews. 2023 Sep 7;201:115084. doi: 10.1016/j.addr.2023.115084. (IF 16.1)
4. Lee C, Chen R, Sun G, Liu X, Lin X, He C, et al. VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway. Signal Transduction and Targeted Therapy. 2023 Aug 18;8(1):305 (IF 39.3)
5. Hosaka K, Andersson P, Wu J, He X, Du Q, Jing X, et al. KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas. Proceedings of the National Academy of Sciences of the United States of America. 2023 Jul 18;120(29):e2303740120. (IF 11.1)
6. Wu J, Jing X, Du Q, Sun X, Holgersson K, Gao J, et al. Disruption of the clock component Bmal1 in mice promotes cancer metastasis through the PAI-1-TGF-β-myoCAF-dependent mechanism. Advanced Science. 2023 Jun 17;e2301505. (IF 15.1)
7. Hosaka K, Wang C, Zhang S, Lv X, Seki T, Zhang Y, et al. Perivascular localized cells commit erythropoiesis in PDGF-B-expressing solid tumors. Cancer Communications. 2023 Jun;43(6):637-660. (IF 16.2, Cover article)
8. Jing X, Wu J, Dong C, Gao J, Seki T, Kim C, et al. COVID-19 instigates adipose browning and atrophy through VEGF in small mammals. Nature Metabolism. 2022 Dec;4(12):1674-1683 (IF 20.8)
9. Xie S, Jiang C, Wu M, Ye Y, Wu B, Sun X, et al. Dietary ketone body-escalated histone acetylation in megakaryocytes alleviates chemotherapy-induced thrombocytopenia. Science Translational Medicine. 2022 Nov 30;14(673):eabn9061 (IF 17.1, Cover article)
10. Yang Y. Editorial: The Adipose Tissue Microenvironment in Cancer: Molecular Mechanisms and Targets for Treatment. Frontiers in Cell and Developmental Biology. 2022 Oct 19;13:954645. (IF 5.5)
11. Du Q, Wu J, Fischer C, Seki T, Jing X, Gao J, et al. Generation of mega brown adipose tissue in adults by controlling brown adipocyte differentiation in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2022 Oct 4;119(40):e2203307119. (IF 11.1)
12. Sun Q, Wang Y, Ji H, Sun X, Xie S, Chen L, et al. Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma. Cell Death & Disease. 2022 Aug 19; 13(8):724.doi: 10.1038/s41419-022-05171-3.(IF 9.0)
13. Qi M, Fan S, Huang M, Pan J, Li Y, Miao Q, et al. Targeting FAPα-expressing hepatic stellate cells overcomes resistance to anti-angiogenics in colorectal cancer liver metastasis models.Journal of Clinical Investigation. 2022 Oct 3;132(19):e157399. doi: 10.1172/JCI157399. (IF 15.9)
14. Seki T, Yang Y, Sun X, Lim S, Xie S, Guo Z, et al. Brown fat-mediated tumor suppression by cold-altered global metabolism. Nature. 2022 Aug;608(7922):421-428. doi: 10.1038/s41586-022-05030-3. (IF 64.8, ESI Highly Cited Paper, Research Highlights in Nature Reviews Endocrinology)
15. Wang Y, Sun Q, Ye Y, Sun X, Xie S, Zhan Y, et al. FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis. JCI Insight. 2022 Apr 19;e157874 (IF 8.0)
16. Yang Y, Cao Y. The impact of VEGF on cancer metastasis and systemic disease. Seminars in Cancer Biology. 2022 Mar 17;86(Pt 3):251-261. doi: 10.1016/j.semcancer.2022.03.011. (IF 14.5, ESI Highly Cited Paper)
17. Zhang R, Yang Y, Dong W, Lin M, He J, Zhang X, et al. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proceedings of the National Academy of Sciences of the United States of America. 2022 Feb 22;119 (8):e2114851119 (IF 11.1)
18. Xu X, Mu L, Li L, Liang J, Zhang S, Jia L, et al. Imaging and tracing the pattern of adult ovarian angiogenesis implies a strategy against female reproductive aging. Science Advances. 2022 Jan 14;8(2):eabi8683 (IF 13.6)
19. Wu B, Ye Y, Xie S, Li Y, Sun X, Lv M. et al. Megakaryocytes mediate hyperglycemia-induced tumor metastasis. Cancer Research.2021 Nov 1;81(21):5506-5522 (IF 11.2)
20. Wu J, Chen Z, Wickström S, Gao J, He X, Jing X, et al. IL-33 is a novel immunosuppressor that protects cancer cells from TIL killing by a macrophage-mediated shedding mechanism. Advanced Science. 2021 Sep 5:e2101029 (IF 15.1)
21. Qiu M, Duo Y, Liang W, Yang Y, Zhang B, Xie Z, et al. Nanopoxia: Targeting cancer hypoxia by antimonene-based nanoplatform for precision cancer therapy. Advanced Functional Materials. 2021 Jul 28; doi:10.1002/adfm.202104607 (IF 19.0)
22. Huang M, Chen M, Qi M, Ye G, Pan J, Shi C, et al. Perivascular cell-derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs. Journal of Extracellular Vesicles. 2021 May;10(7):e12096. (IF 16.0)
23. Sun X, He X, Zhang Y, Hosaka K, Andersson P, Wu J, et al. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. Gut. 2022 Jan;71(1):129-147. doi: 10.1136/gutjnl-2020-322744. Epub 2021 Feb 10 (IF 24.5)
24. Liu Q, Xie Z, Qiu M, Shim I, Yang Y, Xie S, et al. Prodrug-loaded zirconium carbide nanosheets as a novel bio-photonic nanoplatform for effective treatment of cancer. Advanced Science. 2020 Nov 5;7(24):2001191 (IF 15.1)
25. Hosaka K, Yang Y, Seki T, Du Q, Jing X, He X, et al. Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors. Nature Communications. 2020 Jul 24;11(1):3704. (IF 16.6)
26. Ali Z, Cui D, Yang Y, Tracey-White D, Vazquez-Rodriguez G, Moosajee M, et al. Synchronized tissue-scale vasculogenesis and ubiquitous lateral sprouting underlie the unique architecture of the choriocapillaris. Developmental Biology. 2020 Jan 15;457(2):206-214. (IF 2.7)
27. Sui W, Li H, Yang Y, Jing X, Xue F, Cheng J, et al. Bladder drug mirabegron exacerbates atherosclerosis through activation of brown fat-mediated lipolysis. Proceedings of the National Academy of Sciences of the United States of America. 2019 May 28;116(22):10937-10942. (IF 11.1)
28. Andersson P, Yang Y, Hosaka K, Zhang Y, Fischer C, Braun H, et al. Molecular mechanisms of IL-33-mediated stromal interactions in cancer metastasis. JCI Insight. 2018 Oct 18;3(20):e122375. (IF 8.0)
29. Iwamoto H, Abe M, Yang Y, Seki T, Nakamura M, Hosaka K, et al. Cancer lipid metabolism confers antiangiogenic drug resistance. Cell Metabolism. 2018 Jul 3;28(1):104-117.e5. (IF 29.0; >100 times cited)
30. Feng X, Classon C, Terán G, Yang Y, Li L, Chan S, et al. Atrophy of skin-draining lymph nodes predisposes for impaired immune responses to secondary infection in mice with chronic intestinal nematode infection. PLoS Pathogens. 2018 May 17;14(5):e1007008. (IF 6.7)
31. Hosaka K, Yang Y, Nakamura M, Andersson P, Yang X, Zhang Y, et al. Dual roles of endothelial FGF-2-FGFR1-PDGF-BB and perivascular FGF-2-FGFR2-PDGFRβ signaling pathways in tumor vascular remodeling. Cell Discovery. 2018 Jan 16;4:3. (IF 33.5)
32. Fischer C, Seki T, Lim S, Nakamura M, Andersson P, Yang Y, et al. A miR-327-FGF10-FGFR2-mediated autocrine signaling mechanism controls white fat browning. Nature Communications. 2017 Dec 12;8(1):2079. (IF 16.6)
33. Nakamura M, Zhang Y, Yang Y, Sonmez C, Zheng W, Huang G, et al. Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production. Proceedings of the National Academy of Sciences of the United States of America. 2017 Nov 7;114(45):E9635-E9644. (IF 11.1)
34. Zhang Y, Sun M, Huang G, Yin L, Lai Q, Yang Y, et al. Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy. Proceedings of the National Academy of Sciences of the United States of America. 2017 Jun 27;114(26):E5226-E5235. (IF 11.1)
35. Liu C, Zhang Y, Lim S, Hosaka K, Yang Y, Pavlova T, et al. A Zebrafish Model Discovers a Novel Mechanism of Stromal Fibroblast-Mediated Cancer Metastasis. Clinical Cancer Research. 2017 Aug 15;23(16):4769-4779. (IF 11.5)
36. Hosaka K, Yang Y, Seki T, Fischer C, Dubey O, Fredlund E, et al. Pericyte-fibroblast transition promotes tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America. 2016 Sep 20;113(38):E5618-27. (IF 11.1)
37. Yang Y, Zhang Y, Iwamoto H, Hosaka K, Seki T, Nakamura M, et al. Discontinuation of anti-VEGF treatment triggers host VEGF-dependent revascularization-induced metastasis. Nature Communications. 2016 Sep 1;7:12680 (IF 16.6; >100 times cited)
38. Seki T, Hosaka K, Lim S, Honek J, Yang Y, Fischer C, et al. Endothelial PDGF-CC mediates VEGF-dependent paracrine regulation of adipocyte function in beige adipose tissues. Nature Communications. 2016 Aug 5;7:12152 (IF 16.6)
39. Yang Y, Andersson P, Hosaka K, Zhang Y, Cao R, Iwamoto H, et al. The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages. Nature Communications. 2016 May 6;7:11385 (IF 16.6; >100 times cited)
40. Zhang Y, Yang Y, Hosaka K, Huang G, Zang J, Chen F, et al. Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy. Proceedings of the National Academy of Sciences of the United States of America. 2016 Apr 12;113(15):4158-63 (IF 11.1)
41. Iwamoto H, Zhang Y, Seki T, Yang Y, Nakamura M, Wang J, et al. PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors. Science Advances. 2015 Apr 10;1(3):e1400244 (IF 13.6)
42. Yang X, Zhang Y, Hosaka K, Andersson P, Wang J, Tholander F, et al. VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 2015 Jun 2;112(22):E2900-9. (IF 11.1)
43. Cao R, Ji H, Yang Y, Cao Y. Collaborative effects between the TNF-a-TNFR1-macrophage axis and the VEGF-C-VEGFR3 signaling in lymphangiogenesis and metastasis. OncoImmunology. 2015 Jan 22;4(3):e989777 (IF 7.2)
44. Ji H, Cao R, Yang Y, Zhang Y, Iwamoto H, Lim S, et al. TNFR1 mediates TNF-a-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling Nature Communications. 2014 Sep 17;5:4944. (IF 16.6; >100 times cited)
45. Yang X, Zhang Y, Yang Y, Lim S, Cao Z, Rak J, et al. Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 2013 Aug 20;110(34):13932-7. (IF 11.1)
46. Yang Y, Zhang Y, Cao Z, Wahlberg E, Lanne T, Sun B, et al. Anti-VEGF- and anti-VEGFR- induced vascular alteration in mouse healthy tissues. Proceedings of the National Academy of Sciences of the United States of America. 2013 Jul 16;110(29):12018-23. (IF 11.1; >100 times cited)
47. Hosaka K, Yang Y, Rouhi P, Jensen L, Xue Y, Lim S, et al. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. Nature Communications. 2013;4:2129. (IF 16.6)
48. Hedlund EM, Yang X, Zhang Y, Yang Y, Shibuya M, Zhong W, et al. Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(2):654-659. (IF 11.1)
49. Yang Y, Lin Y, Yue Z, Xinghua G, Fang F, Aijun S, et al. Taurine detected by HRMAS 1H NMR: a potential indicator of early myocardial infarction. Experimental and Therapeutic Medicine. 2013;5(3):683-688. (IF 2.7)
50. Xue Y, Lim S, Yang Y, Wang Z, Jensen LD, Hedlund EM, et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nature Medicine. 2012;18(1):100-110. (IF 82.9, commented in Nature Medicine)
51. Jensen LD, Cao Z, Nakamura M, Yang Y, Brautigam L, Andersson P, et al. Opposing effects of circadian clock genes bmal1 and period2 in regulation of VEGF-dependent angiogenesis in developing zebrafish. Cell Reports. 2012;2(2):231-241. (IF 8.8)
52. Yang L, Guo W, Zhang Q, Li H, Liu X, Yang Y, et al. Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by Grp75 under glucose deprivation conditions. Journal of Molecular Biology. 2011;414(5):654-666. (IF 5.6)
53. Cao R, Lim S, Ji H, Zhang Y, Yang Y, Honek J, et al. Mouse corneal lymphangiogenesis model. Nature Protocols. 2011;6(6):817-826 (IF 14.8)